The results showed a significant reduction in body weight, with a weight loss rate of 19.43%, indicating substantial anti-obesity potential
Yes, like all medications, GLP-1 RAs can cause side effects
doi: 10.1016/j.bbr.2018.08.006 Summary Keywords Alzheimers disease, GLP-1R agonists, cognitive function, amyloid beta, tau phosphorylation Citation Du H, Meng X, Yao Y and Xu J (2022) The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimers disease
Lending support to this hypothesis, a recent imaging study demonstrated that GLP-1 reduces activity in parts of the brain involved in appetite and reward in people with Type 2 diabetes and obesity
While the long-term safety and effectiveness of GLP-1RA for other indications like kidney disease and fatty liver still need verification, attention and research investment in GLP-1RAs for obesity and related conditions are keeping increasing, driving further scientific and medical advancements in metabolic diseases
The research suggests that people who hold steady through the first 90 days have dramatically better long-term outcomes